Kazia Therapeutics Limited (NV9M.F)
| Previous close | 7.50 |
| Open | 7.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 7.50 - 7.50 |
| 52-week range | 4.60 - 12.50 |
| Volume | |
| Avg. volume | 36 |
| Market cap | 101.595M |
| Beta (5Y monthly) | 2.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.77 |
| Earnings date | 27 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.04 |
PR NewswireKAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that the Safety Review Team (SRT) of the EVT801 Phase 1 clinical trial has concluded that the primary and secondary objectives of stage 1 of the trial have successfully been met.
- PR Newswire
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that it has entered into an exclusive licensing agreement with Sovargen Co., Ltd, a biotechnology company specializing in central nervous system (CNS) diseases, to develop, manufacture and commercialise paxalisib as a potential treatment of intractable epilepsy in focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC) disease. The underlying cause of FCD T2 a
- PR Newswire
Kazia announces presentation of new data at AACR Annual Meeting
Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce the presentation of new data for both its pipeline molecules, paxalisib and EVT801, at the upcoming Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California, from 5-10 April 2024.
